WASHINGTON, July 27, 2009 (GLOBE NEWSWIRE) -- Finkelstein Thompson LLP is investigating potential shareholder claims arising from the tender offer by which the board of directors of Medarex, Inc. ("Medarex" or the "Company") (Nasdaq:MEDX) has agreed to sell the Company to Bristol-Myers Squibb ("Bristol-Meyers"). Under the terms of the offer, Medarex shareholders will receive $16.00 per share in cash -- valuing the sale at $2.4 billion. The tender offer price is well below Medarex' peak historical share price and appears to be timed to take advantage of widespread depressed equities prices due to the global economic downturn.
The investigation is focused on the potential unfairness of the tender offer price and of the process by which the Medarex board of directors approved the offer.
If you are interested in discussing your rights as a Medarex shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com.